Table 2.
Clinicopathologic characteristics of patients with stage IB3 cervical cancer in the NACT and ARH groups.
| Variables | Unadjusted | Adjusted | ||||
|---|---|---|---|---|---|---|
| NACT group (n = 583) | ARH group (n = 827) | p | NACT group (n = 490) | ARH group (n = 490) | p | |
| Age (years) | 45.38 ± 7.748 | 47.20 ± 8.672 | <0.001 | 45.57 ± 7.336 | 45.66 ± 7.407 | 0.842 |
| Initial tumor diameter (cm) | 5.369 ± 0.871 | 5.387 ± 1.036 | 0.736 | 5.365 ± 0.872 | 5.376 ± 1.012 | 0.856 |
| Histological type | 0.208 | 0.942 | ||||
| SCC | 514 (88.2%) | 726 (87.8%) | 434 (88.6%) | 437 (89.2%) | ||
| AC | 59 (10.1%) | 75 (9.1%) | 48 (9.8%) | 46 (9.4%) | ||
| SAC | 10 (1.7%) | 26 (3.1%) | 8 (1.6%) | 7 (1.4%) | ||
| Parametrial involvement | 0.358 | 0.762 | ||||
| Negative | 576 (98.8%) | 821 (99.3%) | 485 (99.0%) | 484 (98.8%) | ||
| Positive | 7 (1.2%) | 6 (0.7%) | 5 (1.0%) | 6 (1.2%) | ||
| Vaginal margin invasion | 0.844 | 1.000 | ||||
| Negative | 576 (98.8%) | 818 (98.9%) | 485 (99.0%) | 485 (99.0%) | ||
| Positive | 7 (1.2%) | 9 (1.1%) | 5 (1.0%) | 5 (1.0%) | ||
| LVSI | <0.001 | <0.001 | ||||
| Negative | 549 (94.2%) | 724 (87.5%) | 463 (94.5%) | 421 (85.9%) | ||
| Positive | 34 (5.8%) | 103 (12.5%) | 27 (5.5%) | 69 (14.1%) | ||
| Stromal invasion | <0.001 | <0.001 | ||||
| ≤1/2 | 273 (46.8%) | 237 (28.6%) | 227 (46.3%) | 138 (28.2%) | ||
| >1/2 | 256 (43.9%) | 549 (66.4%) | 220 (44.9%) | 330 (67.3%) | ||
| Unknown | 54 (9.3%) | 41 (5.0%) | 43 (8.8%) | 22 (4.5%) | ||
| Postoperative radiotherapy | <0.001 | <0.001 | ||||
| No | 363 (62.3%) | 388 (46.9%) | 301 (61.4%) | 240 (49.0%) | ||
| Yes | 220 (37.7%) | 439 (53.1%) | 189 (38.6%) | 250 (51.0%) | ||
NACT, neoadjuvant chemotherapy; ARH, abdominal radical hysterectomy; SCC, squamous cell carcinoma; AC, adenocarcinoma; SAC, adenosquamous carcinoma; LVSI, lymphovascular space invasion.